Sanofi's Acomplia Stumbles
It seems FDA isn't as comfortable as some thought about letting Sanofi-Aventis' much-vaunted obesity candidate rimonabant (Acomplia) onto the market. But the agency's caution--and that's all it appears to be--isn't so surprising.
You may also be interested in...
Sanofi-Aventis' investigational weight loss drug rimonabant will be the subject of a high-profile advisory committee review smack in the midst of a sensitive political environment for FDA. But even if Sanofi manages to eke out an approval, it will face yet another marketing challenge: the loss of the well-recognized brand name Acomplia.
Wall Street analysts are confident that Congress will pass drug safety legislation this year, but in a poll conducted by The RPM Report, they didn't agree on much else. The panel was split most other questions-from whether Congress would remove the "non-interference" clause under Medicare Part D to whether FDA would approve another cox-2 inhibitor.
As Acomplia is launched across Europe, Sanofi Aventis' challenge is less about promoting the drug, than about limiting its use within the appropriate target group.